AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15560843
Drug: Intensive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive group training protocol combining exercise therapy with principles of behavioural therapy and back school
Trial: 3145064
Drug: 125I labelled
RxNorm normalized name: fibrinogen (125I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125I labelled soluble human insulin (0.05 U/kg)
Trial: 3145064
Drug: Insulin analogue
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin analogue (0.05 U/kg)
Trial: 3145064
Drug: 125I labelled
RxNorm normalized name: fibrinogen (125I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125I labelled soluble human insulin (0.1 U/kg)
Trial: 3145064
Drug: Insulin analogue
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin analogue (0.1 U/kg)
Trial: 3145064
Drug: Soluble insulin
RxNorm normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soluble insulin (0.05 U/kg)
Trial: 3145064
Drug: Soluble insulin
RxNorm normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soluble insulin (0.1 U/kg)
Trial: 29862411
Drug: everolimus plus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: everolimus plus exemestane (10 mg/d + 25 mg/d)
Trial: 29862411
Drug: everolimus alone
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: everolimus alone (10 mg/d)
Trial: 29862411
Drug: capecitabine alone
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine alone (1250 mg/m2 twice daily)
Trial: 23306596
Drug: Incredible Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incredible Years Toddler Parenting Program (12 sessions) under research contexts (with weekly supervision)
Trial: 18947487
Drug: GOS-formula feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOS-formula feeding (2.4 g/L)
Trial: 15843764
Drug: Reboxetine at
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine at a dose of 4 mg/day
Trial: 12592082
Drug: Bexarotene (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexarotene (oral or topical gel)
Trial: 10470423
Drug: 5-FU 450
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 450 mg/m2 plus Levamisol (B)
Trial: 10470423
Drug: 5-FU 600
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 600 mg/m2 (C)
Trial: 8767614
Drug: Propafenone 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 450 mg as single dose followed by 300 mg t.i.d.
Trial: 8767614
Drug: Hydroquinidine 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroquinidine 900 mg/24 hours + digoxin if necessary
Trial: 1826073
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg morphine (group B)
Trial: 1826073
Drug: 30 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 micrograms sufentanil plus 3 mg morphine (group C)
Trial: 6991534
Drug: Proquazone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proquazone (300 mg)
Trial: 6991534
Drug: New formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulations of analgesic combinations (aminophenazone replaced by propyphenazone)
Trial: 6991534
Drug: Aspirin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (250 mg)
Trial: 6991534
Drug: Aspirin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1000 mg) vs Placebo
Trial: 28222149
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment (20, 40, and 60 mg/kg)
Trial: 25887550
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment (MMT) including neurophysiological education, sensory training, and motor training, with up to 16 sessions over 8 to 12 weeks and additional home training of 10 to 30 minutes five times per week.
Trial: 25887550
Drug: Usual physiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual physiotherapy treatment (UPT), with up to 16 sessions over 8 to 12 weeks and additional home training of 10 to 30 minutes five times per week.
Trial: 25887550
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment (MMT)
Trial: 25887550
Drug: Usual physiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual physiotherapy treatment (UPT)
Trial: 19636365
Drug: Pentavalent antimony
RxNorm normalized name: Pentavalent Antimony
DrugBank: Pentavalent Antimony (DB13047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent antimony plus 5% imiquimod cream applied to each lesion three times per week for 20 days
Trial: 19636365
Drug: Pentavalent antimony
RxNorm normalized name: Pentavalent Antimony
DrugBank: Pentavalent Antimony (DB13047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent antimony plus placebo (vehicle cream) applied as above
Trial: 16454145
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate nasal spray (10 mmol)
Trial: 11410114
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg for 8 weeks
Trial: 7686216
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 IV day 1 and Vinblastine 6 mg/m2 IV days 1 and 2 every 3 weeks (PV)
Trial: 7686216
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 IV day 1 and Vinblastine 6 mg/m2 IV days 1 and 2 every 3 weeks with Bleomycin 30 mg IM weekly (PVB)
Trial: 26630538
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral medroxyprogesterone acetate (MPA) administered for 10 days per cycle for 6 months
Trial: 26630538
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral medroxyprogesterone acetate (MPA) administered daily for 6 months
Trial: 22134043
Drug: Haloperidol (2.5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (2.5‐10 mg/day)
Trial: 16708310
Drug: CRP test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP test (above 50 mg/l)
Trial: 22808045
Drug: Heated blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated blood transfusion/fluid infusion
Trial: 20479297
Drug: Etanercept, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept, 50 mg, SC administered twice weekly for 12 weeks
Trial: 18184958
Drug: HES therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES therapy
Trial: 15844469
Drug: DHEA replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA replacement (50 mg/day)
Trial: 15318461
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil (1 microg kg(‐1))
Trial: 15318461
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil (3 microg kg(‐1))
Trial: 15318461
Drug: Remifentanil (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (any dose)
Trial: 11386092
Drug: Bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.125% plus 0.5 microgram ml‐1 sufentanil
Trial: 8128328
Drug: Endoscopic thrombin
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic thrombin injections in actively bleeding patients (group II, N = 94)
Trial: 8128328
Drug: Endoscopic thrombin
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic thrombin injections in non-bleeding visible vessels (group A, N = 25)
Trial: 8128328
Drug: No primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No primary endoscopic treatment in non-bleeding visible vessels (group B, N = 25)
Trial: 26731401
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between treatment and control groups during the intervention period.
Trial: 12572380
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy + QHBDY
Trial: 8556909
Drug: Mifepristone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 150 mg single dose treatment
Trial: 8556909
Drug: Early pregnant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early pregnant cervix before treatment
Trial: 2242521
Drug: Nifedipine-ISDN combination
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine-ISDN combination
Trial: 577428
Drug: Benzopyrone compound
RxNorm normalized name: benzopyrene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzopyrone compound Venalot (2 depot tablets b.d.)
Trial: 19014751
Drug: Divalproex (500‐2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divalproex (500‐2500 mg/day)
Trial: 16292090
Drug: S. boulardii
RxNorm normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. boulardii 500 mg twice daily
Trial: 12785003
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion (40 microg/kg/min)
Trial: 1667753
Drug: Pyrophosphate dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrophosphate dentifrice (F-Antibelag Gel + K4P2O7/Na4P2O7)
Trial: 1667753
Drug: Placebo (F-Antibelag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (F-Antibelag Gel)
Trial: 31262153
Drug: Maximal strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal strength training (twice a week for 3 months)
Trial: 31262153
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (prescribed treatment without strength training)
Trial: 24623024
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (IT) with a target blood glucose range of 4.4‐6.1 mmol/L
Trial: 24623024
Drug: Intermediate insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate insulin therapy (IT) with a target blood glucose range of 7.7‐10.0 mmol/L
Trial: 17941876
Drug: Nateglinide monotherapy
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide monotherapy (120 mg before meals)
Trial: 17941876
Drug: Nateglinide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (120 mg before meals) + Metformin (up to 1000 mg bid)
Trial: 17941876
Drug: Glyburide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide (up to 5 mg bid) + Metformin (up to 1000 mg bid)
Trial: 12802092
Drug: Tongue strengthening
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongue strengthening exercises using the Iowa Oral Performance Instrument
Trial: 11105936
Drug: Cocaine (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (0.9 mg/kg)
Trial: 9065557
Drug: Hu-related molecules
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hu-related molecules of 35 to 41 kDa detected in the membrane of small-cell lung cancers and neuroblastomas using immunofluorescence, absorption assays, Western blotting on membrane fractions, and surface biotinylation.
Trial: 8452191
Drug: Amoxicillin 3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 3,000 mg
Trial: 2878173
Drug: Warfarin started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin started within 3 days of heparin (group S)
Trial: 2878173
Drug: Warfarin started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin started after 7 days of heparin (group L)
Trial: 29878341
Drug: DFN-02 (sumatriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-02 (sumatriptan 10 mg with DDM)
Trial: 12699521
Drug: Ketamine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.1 mg kg(‐1) i.m. premedication
Trial: 11033836
Drug: rhIL-11 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-11 in combination with G-CSF (filgrastim)
Trial: 9193196
Drug: High-dose quetiapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose quetiapine fumarate (<= 750 mg/d)
Trial: 9193196
Drug: Low-dose quetiapine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose quetiapine fumarate (<= 250 mg/d)
Trial: 28030431
Drug: LCZ696/amlodipine (200/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696/amlodipine (200/5 mg/day)
Trial: 15803442
Drug: Thrombolytic drug
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic drug regimens
Trial: 12296638
Drug: Tirilazad treatment
RxNorm normalized name: TIRILAZAD
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad treatment in patients with TBI
Trial: 7637174
Drug: Ulinastatin (12,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (12,000 units.kg‐1) administered 15 min after starting CPB in the bubble oxygenator group
Trial: 73313
Drug: Levamisole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (150 mg daily for 3 days every second week)
Trial: 30565718
Drug: High-protein oral
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein oral nutrition supplement (S-ONS)
Trial: 17185047
Drug: Colistin dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin dry powder inhalation (25 mg)
Trial: 17185047
Drug: Nebulised colistin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised colistin (158 mg)
Trial: 15584584
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (remifentanyl and propofol)
Trial: 15584584
Drug: Inhaled anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled anaesthesia (isoflurane and fentanyl)
Trial: 11466098
Drug: Daily pacifier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pacifier use (observational analysis)
Trial: 8301443
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) at doses from 5 to 80 ppm
Trial: 2732981
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg metronidazole (two sponges per day for two days)
Trial: 2732981
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg metronidazole (one sponge per day for three days)
Trial: 30940189
Drug: Irinotecan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan plus S‐1 (intravenous infusion of irinotecan [160 mg/m2] on day 1 and oral S‐1 [80‐120 mg] on days 1‐10, repeated every 14 days)
Trial: 30940189
Drug: S‐1 monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐1 monotherapy (80‐120 mg/day on days 1‐14, repeated every 21 days)
Trial: 28081543
Drug: S‐1 monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐1 monotherapy
Trial: 25011019
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (85,300 IU weekly for 1 year)
Trial: 24682069
Drug: Aleglitazar 150
RxNorm normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aleglitazar 150 µg daily
Trial: 19956761
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g) given at 16-24 and 28-32 weeks gestation
Trial: 17725940
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg orally 3 times, beginning the day before ERCP until the night after the procedure.
Trial: 17725940
Drug: No preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preventive medication (Control group).
Trial: 17725940
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg orally.
Trial: 16095435
Drug: Ceftriaxone sodium
RxNorm normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone sodium as empiric therapy with physician notification
Trial: 7744150
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei preparation (BLP)
Trial: 7057051
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (Fluocinonide)
Trial: 30790396
Drug: Intramyocardial injections
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injections of allogeneic Cardiology Stem Cell Centre Adipose-derived Stromal Cells (CSCC_ASC)
Trial: 23916044
Drug: Retigabine/ezogabine (600-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retigabine/ezogabine (600-1200 mg/d)
Trial: 19813275
Drug: Amifostine (740
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (740 mg/m2 intravenously over 15 minutes before each administration of a platinum agent)
Trial: 14984396
Drug: Citalopram (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (mean dose 26.3 mg)
Trial: 11679464
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg b.i.d. for 6 months
Trial: 11679464
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 6 months
Trial: 23832078
Drug: ONS (Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONS (Oral Nutritional Supplement)
Trial: 23832078
Drug: ONS800 (ONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONS800 (ONS plus 800 mg beta-alanine)
Trial: 23832078
Drug: ONS1200 (ONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONS1200 (ONS plus 1200 mg beta-alanine)
Trial: 19545479
Drug: Anger treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anger treatment program
Trial: 16434603
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy and cognitive behavioral therapy
Trial: 15541080
Drug: Newly developed
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly developed combination therapy for diabetic ulcers with exposed bones (n = 11)
Trial: 15541080
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for diabetic ulcers without exposed bones (n = 8)
Trial: 11384563
Drug: Emedastine 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emedastine 0.05% eye drops, administered twice daily for 6 weeks
Trial: 11384563
Drug: Levocabastine 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine 0.05% eye drops, administered twice daily for 6 weeks
Trial: 7967703
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated wholly with Western drugs
Trial: 21346162
Drug: Mood-elevating suggestion
RxNorm normalized name: RELACORE STRESS REDUCER/MOOD ELEVATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mood-elevating suggestion before ketamine administration
Trial: 6344034
Drug: Fendosal 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fendosal 200 mg
Trial: 6344034
Drug: Fendosal 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fendosal 400 mg
Trial: 26440233
Drug: Sodium thiopental
RxNorm normalized name: Thiopental Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium thiopental 1.5 mg/kg
Trial: 17342995
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional drug (Blank group)
Trial: 15112871
Drug: Cefazolin 1
RxNorm normalized name: cefazolin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 gr. i.v. preoperative and every 8 hrs. during the first day (3 doses) followed by ciprofloxacin 250 mg. oral every 12 hrs until catheter removal.